Jeffrey S. Buguliskis, PhD
Jeff is deputy chief editor of Outsourced Pharma, where he translates complex biology and manufacturing into practical guidance for drug sponsors navigating CDMO selection, tech transfer, analytics, and timelines. He holds a PhD in Molecular Cell Biology from Thomas Jefferson University and a BS in Biology from the University of the Sciences in Philadelphia. His editorials reflect two decades spanning bench science, publishing, and industry, and are written to help readers see both the big-picture dynamics and on-the-ground realities of outsourcing.
Prior to Outsourced Pharma, Buguliskis served as a technical editor at Genetic Engineering & Biotechnology News (GEN), where he authored features and hosted GEN’s “GenCast” podcast series and managed multimedia initiatives at Mary Ann Liebert Publishing. Afterwards, Jeff engaged audiences with his editorial leadership as Director of Content at SynBioBeta. Earlier in his career, he conducted postdoctoral research in molecular microbiology at Washington University in St. Louis, publishing on parasite invasion mechanisms—including a widely cited Toxoplasma gondii study on the rhomboid protease ROM4. These experiences inform his science-minded, operations-aware voice across the outsourcing lifecycle.
Jeff is an avid Philly sports fan, homebrewer, and foodie.
ARTICLES BY JEFFREY S. BUGULISKIS, PHD
-
![Fashion Designer-GettyImages-915237522]( "Six Specialized Modalities Testing CDMO Readiness In 2026")
Six Specialized Modalities Testing CDMO Readiness In 20262/27/2026As biopharma pipelines shift toward more complex therapies, sponsors are finding that CDMO readiness now depends less on general capacity and more on highly specific technical capabilities.
-
![Conductor directing symphony orchestra-GettyImages-490338206]( "End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight")
End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight2/6/2026ADC success is less about perfect execution and more about early signal detection, tight communication, and decisive governance.
-
![Calendar page January of year 2026 with To-do lists-GettyImages-2161128897]( "7 Outsourcing Behaviors for 2026 That Will Protect Timelines")
7 Outsourcing Behaviors for 2026 That Will Protect Timelines12/29/2025Protecting manufacturing timelines in 2026 means converting speed from a hope into a contractual commitment through strategic prepayment, integrated partnerships, and formalized accountability.
-
![scattered tablets form continents-GettyImages-1150573566]( "The Top 10 Nations Redrawing The Outsourcing Map")
The Top 10 Nations Redrawing The Outsourcing Map12/8/2025There was a time when your outsourcing strategy could be managed with a simple spreadsheet and a focus on cost-per-liter. Those days are gone…
-
![AI, artificial intelligence in healthcare-GettyImages-2187633236]( "How AI Is Rewriting Tech Transfer Timelines")
How AI Is Rewriting Tech Transfer Timelines11/26/2025By replacing trial-and-error with virtual simulations and predictive analytics, AI is giving even small biotechs the process development capabilities once reserved for Big Pharma—and slashing tech transfer timelines in the process.
-
![growing chart of medical pills-GettyImages-2159767302]( "The 9 Fastest-Growing Outsourcing Segments")
The 9 Fastest-Growing Outsourcing Segments10/21/2025Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
-
![Robotic arm, golden capsule, dna-GettyImages-1367497961]( "Cell & Gene Therapy Outsourcing's New Paradigm")
Cell & Gene Therapy Outsourcing's New Paradigm10/7/2025The industry has flipped from scarcity to surplus, and sponsors now have leverage to set terms, not take numbers.
-
![GettyImages-1308446684]( "Clear The Outsourcing Runway: The 8 Largest Deals In The Past Year")
Clear The Outsourcing Runway: The 8 Largest Deals In The Past Year9/30/2025We ranked the past year’s eight biggest pharma–CDMO manufacturing deals and decoded what they signal for your next outsourcing project.
-
![Natural medicine, ESG, environmental social governance, medical, healthcare-GettyImages-2153161257]( "Green Is The New KPI: Sustainability In Pharma Outsourcing")
Green Is The New KPI: Sustainability In Pharma Outsourcing9/10/2025Sustainability is moving from marketing to metering, as sponsors look for facility-level metrics and contract incentives that drive measurable improvement.
